According to a newly published market research report by 24LifeSciences, the global Compound Ammonium Glycyrrhetate S for Injection market was valued at USD 250 million in 2024 and is projected to reach USD 410 million by 2032, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period 2025–2032.
Compound Ammonium Glycyrrhetate S for Injection, derived from glycyrrhizic acid found in licorice root, is a critical hepatoprotective and anti-inflammatory agent widely used in the treatment of conditions such as chronic hepatitis, drug-induced liver injury, and certain dermatological and allergic disorders. Its established efficacy in stabilizing cell membranes and inhibiting inflammatory mediators continues to underpin its importance in hepatology and clinical medicine.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10551/compound-ammonium-glycyrrhetate-s-for-injection-market
Rising Global Burden of Liver Diseases Fuels Market Growth
The increasing global prevalence of chronic liver diseases, including hepatitis, non-alcoholic fatty liver disease (NAFLD), and drug-induced liver injury (DILI), remains the primary growth driver for this market. The expanding number of patients requiring hepatoprotective therapy, particularly among aging populations and those with long-term medication use, has significantly increased demand for reliable and effective injectable treatments.
In addition, the product's proven role in managing inflammatory skin conditions and allergic reactions ensures a steady and recurring demand from dermatology and immunology departments worldwide.
Advanced Extraction and Purification Technologies Enhance Product Quality
Technological advancements in the extraction and purification of glycyrrhizic acid have transformed the market by improving product purity, batch-to-batch consistency, and overall safety profile. These innovations have strengthened regulatory acceptance and enabled pharmaceutical manufacturers to scale production efficiently, supporting long-term market expansion while reducing dependence on variable natural sources.
Ongoing clinical research exploring novel therapeutic applications, including adjunct use in oncology to mitigate chemotherapy side effects, is further opening new growth avenues for this specialized market.
Market Challenges: Regulatory Hurdles and Competitive Pressures
Despite positive growth trends, the market faces notable challenges:
-
Stringent regulatory requirements for injectable botanical drugs in major markets
-
High manufacturing costs associated with specialized extraction and purification processes
-
Competition from alternative hepatoprotective agents including synthetic drugs and other herbal extracts
-
Potential side effects such as pseudohyperaldosteronism with prolonged use, requiring careful patient monitoring
Additionally, supply chain vulnerabilities for quality licorice root and pricing pressures in cost-sensitive healthcare markets have intensified competitive dynamics.
Get the Complete Report & Table of Contents: https://www.24lifesciences.com/compound-ammonium-glycyrrhetate-s-for-injection-market-10551
Asia-Pacific Dominates the Global Market
The Asia-Pacific region, led by China, dominates the global Compound Ammonium Glycyrrhetate S for Injection market, accounting for the majority of both production and consumption. This leadership is driven by:
-
High prevalence of liver diseases and strong tradition of botanical medicine
-
Established domestic pharmaceutical manufacturing capabilities
-
Favorable regulatory frameworks for traditional medicine derivatives
-
Growing healthcare expenditure and expanding hospital infrastructure
North America and Europe remain important secondary markets, supported by advanced healthcare systems and growing acceptance of evidence-based botanical therapies.
Hospital Segment Leads Market by Application
By application, hospital pharmacies represent the largest and most critical segment due to the injectable nature of the product requiring professional administration and monitoring.
By product type, 40mg formulations hold the dominant share owing to their versatility in dosing, established clinical protocols, and widespread availability across treatment settings.
Competitive Landscape: Concentrated with Strong Regional Specialization
The global Compound Ammonium Glycyrrhetate S for Injection market is moderately consolidated, with the top players collectively accounting for a significant portion of global revenue. The competitive environment is shaped by manufacturing expertise, regulatory compliance, distribution networks, and long-standing relationships with healthcare institutions.
Key companies profiled in the report include:
-
Shanxi PUDE Pharmaceutical
-
Shandong Wego Pharmaceutical
-
Dezhou Deyao Pharmaceutical
-
Jilin Century Hanke Pharmaceutical
-
Qingdao Jinfeng Pharmaceutical
-
Hubei Kangqin Pharmaceutical
-
and More
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/compound-ammonium-glycyrrhetate-s-for-injection-market-10551
Market Opportunities: Emerging Markets and Therapeutic Expansion
Significant growth opportunities exist in emerging markets across Latin America, Middle East, and Africa, supported by improving healthcare access and rising awareness of hepatoprotective therapies. Furthermore, the development of novel formulation technologies, including sustained-release systems and combination products, is expected to generate new intellectual property and expand clinical applications.
Access the Full Report
Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/10551/compound-ammonium-glycyrrhetate-s-for-injection-market
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/compound-ammonium-glycyrrhetate-s-for-injection-market-10551
About 24LifeSciences
24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.
Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/